Optimal management of mantle cell lymphoma in the primary setting

References

• Fu S, Wang M, Lairson DR, et al. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and national SEER areas. Oncotarget. 2017;8(68):112516–112529. PubMed PMID: 29348844.
   PubMedGoogle Scholar
• Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009 Feb 1;27(4):511–518. PubMed PMID: 19075279.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Han X, Jemal A, et al. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016 Aug 1;122(15):2356–2363. PubMed PMID: 27153197.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009 Mar 10;27(8):1209–1213. PubMed PMID: 19188674.
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Scott DW, Slack GW, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017 Oct 1;28(10):2489–2495. PubMed PMID: 28961827.
   PubMed Web of Science ®Google Scholar
• Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012 Oct;122(10):3416–3423. PubMed PMID: 23023712; PubMed Central PMCID: PMCPMC3461905.
   PubMed Web of Science ®Google Scholar
• Swerdlow SHCE, Harris NL, Jaffe ES, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2017
   Google Scholar
• McCulloch R, Berrow M, Wainman B, et al. Population based observational study demonstrates significant increase in watch-and-wait for newly diagnosed mantle cell lymphoma. Blood. 2018;132(Suppl 1):2877–2877.
   Google Scholar
• Nordström L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic lymphoma group study. Br J Haematol. 2014;166(1):98–108.
   PubMed Web of Science ®Google Scholar
• Aukema SM, Hoster E, Rosenwald A, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018;131(4):417.
   PubMed Web of Science ®Google Scholar
• Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012 May 3;119(18):4215–4223. PubMed PMID: 22431568; eng.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677–2684. PubMed PMID: 15591112.
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004 Apr 15;22(8):1460–1468. PubMed PMID: 15084619.
   PubMed Web of Science ®Google Scholar
• Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010 Apr 22;115(16):3215–3223. PubMed PMID: 20032498; PubMed Central PMCID: PMCPMC2930903.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565–575. PubMed PMID: 27313086.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016 Nov;175(3):410–418. PubMed PMID: 27378674.
   PubMed Web of Science ®Google Scholar
• Chihara D, Cheah CY, Westin JR, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016 Jan;172(1):80–88. PubMed PMID: 26648336; PubMed Central PMCID: PMCPMC5471614.
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013 Jun;24(6):1587–1593. PubMed PMID: 23504948; PubMed Central PMCID: PMCPMC3660082. eng.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 1;23(28):7013–7023. PubMed PMID: 16145068.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Pedersen LB, Eskelund CW, et al. Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the Nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years. Biol Blood Marrow Transplant. 2017 Mar;23(3):428–435. PubMed PMID: 28039078.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250–1260. PubMed PMID: 28953447.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ferrero S. European Mantle Cell Lymphoma Network. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? Haematologica. 2016 Feb;101(2):104–114. PubMed PMID: 26830211; PubMed Central PMCID: PMCPMC4938333.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Armand P. Minimal residual disease assessment in lymphoma: methods and applications. J Clin Oncol. 2017 Dec 1;35(34):3877–3887. PubMed PMID: 28933999; PubMed Central PMCID: PMCPMC5707209.
   PubMed Web of Science ®Google Scholar
• Loberiza FR, Smith LM, Armitage JO, et al. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group experience AU - Bhatt, Vijaya R. Leuk Lymphoma. 2016 Jun 02;57(6):1327–1334.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Dreyling M. European Mantle Cell Lymphoma Network. Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? Haematologica. 2017;102(7):1133–1136. PubMed PMID: 28655809.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558–565. PubMed PMID: 17962512; eng.
   PubMed Web of Science ®Google Scholar
• Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European Mantle-cell Lymphoma Network. J Clin Oncol. 2014 May 1;32(13):1338–1346. PubMed PMID: 24687837; eng.
   PubMed Web of Science ®Google Scholar
• Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma – consensus guidelines of the pathology panel of the European MCL Network. J Hematopathol. 2009 Jul 01;2(2):103–111.
   PubMedGoogle Scholar
• Bhatt VR, Loberiza FR Jr., Smith LM, et al. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group experience. Leuk Lymphoma. 2016;57(6):1327–1334. PubMed PMID: 26377137.
   PubMed Web of Science ®Google Scholar
• Gerson JN, Handorf E, Villa D, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019;37. DOI:10.1200/JCO.18.00690
   PubMed Web of Science ®Google Scholar
• Ferrer A, Bosch F, Villamor N, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol. 2008 Jan;19(1):135–141. PubMed PMID: 17962207.
   PubMed Web of Science ®Google Scholar
• Bernard M, Gressin R, Lefrere F, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia. 2001 Nov;15(11):1785–1791. PubMed PMID: 11681422; eng.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016 Apr 20;34(12):1386–1394. PubMed PMID: 26926679; eng.
   PubMed Web of Science ®Google Scholar
• Tessoulin B, Eveillard M, Lok A, et al. p53 dysregulation in B-cell malignancies: more than a single gene in the pathway to hell. Blood Rev. 2017 Jul;31(4):251–259. PubMed PMID: 28284458.
   PubMed Web of Science ®Google Scholar
• Halldorsdottir AM, Lundin A, Murray F, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia. 2011 Dec;25(12):1904–1908. PubMed PMID: 21720382.
   PubMed Web of Science ®Google Scholar
• Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2352–2357. PubMed PMID: 16461462; PubMed Central PMCID: PMCPMC1413716.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017 Oct 26;130(17):1903–1910. PubMed PMID: 28819011.
   PubMed Web of Science ®Google Scholar
• Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015 Jul 30;126(5):604–611. PubMed PMID: 26022239.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Zhang MJ, Carreras J, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014 Feb 1;32(4):273–281. PubMed PMID: 24344210; PubMed Central PMCID: PMCPMC3897255.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Ho C, Hilden P, et al. Allogeneic stem cell transplantation overcomes the negative prognostic impact of TP53 alterations in mantle cell lymphoma. Blood. 2018;132(Suppl 1):4668–4668.
   Google Scholar
• Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018 Mar;5(3):e109–e116. PubMed PMID: 29396091.
   PubMed Web of Science ®Google Scholar
• Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211–1223. PubMed PMID: 29590547.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008 Aug 15;113(4):791–798. PubMed PMID: 18615506.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Gressin R. Treatment of the elderly patient with mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):425–431. PubMed PMID: 27913511.
   PubMedGoogle Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203–1210. PubMed PMID: 23433739.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520–531. PubMed PMID: 22873532.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014 May 8;123(19):2944–2952. PubMed PMID: 24591201; PubMed Central PMCID: PMCPMC4260975.
   PubMed Web of Science ®Google Scholar
• Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017 Jan;4(1):e15–e23. PubMed PMID: 27927586.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006 Oct 20;24(30):4867–4874. PubMed PMID: 17001068.
   PubMed Web of Science ®Google Scholar
• Robak T, Jin J, Pylypenko H, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Nov;19(11):1449–1458. PubMed PMID: 30348538.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34(15_suppl):7503–7503.
   Web of Science ®Google Scholar
• Rummel MJ, Maschmeyer G, Ganser A, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study. J Clin Oncol. 2017;35(15_suppl):7501–7501.
   Web of Science ®Google Scholar
• Sun L, Li S, El-Jawahri A, et al. Autologous stem cell transplantation in elderly lymphoma patients in their 70s: outcomes and analysis. Oncologist. 2018 May;23(5):624–630. PubMed PMID: 29284757; PubMed Central PMCID: PMCPMC5947447. eng.
   PubMed Web of Science ®Google Scholar
• Dahi PB, Tamari R, Devlin SM, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014 Dec;20(12):2004–2009. PubMed PMID: 25175794; PubMed Central PMCID: PMCPMC5480286. eng.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012 Jan;23(1):166–171. PubMed PMID: 21467125.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005 Feb 1;23(4):705–711. PubMed PMID: 15598978; eng.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Christos P, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood. 2018 Sep 4. DOI:10.1182/blood-2018-07-859769. PubMed PMID: 30181173.
   Google Scholar
• Wang ML, Lee H, Thirumurthi S, et al. Ibrutinib-rituximab followed by reduced chemo-immunotherapy consolidation in young, newly diagnosed mantle cell patients: a window of opportunity to reduce chemo. Hematol Oncol. 2017;35(S2):142–143.
   PubMedGoogle Scholar